Pozen, which in late November received regulatory approval for the sale of its MT-100 migraine drug in the United Kingdom, got another boost from an analyst firm this week.

Sun Trust Robinson Humphrey initiated coverage of Pozen (Nasdaq: POZN) with a “buy” rating.

Three other firms have launched coverage of Pozen since August 30, each with a “buy” or “outperform” ranking. They were: RBC Capital Markets, First Albany and Jefferies & Co.

Pozen: www.Pozen.com